| Literature DB >> 2719734 |
R T Means1, N J Olsen, S B Krantz, E N Dessypris, S E Graber, W J Stone, V L O'Neil, T Pincus.
Abstract
Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2719734 DOI： 10.1002/anr.1780320519
Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591